Conference Description:

Featuring 30+ presentations, the event brings together over 120 attendees from leading pharma, biotech and academic organisations designing innovative strategies and technologies for more effective cancer immunotherapy development.

Expand your knowledge & discuss future priorities in:

Discovery & Development: Cell Therapies & Antibody Approaches
Biomarkers, Precision Medicine & Spatial Biology in Immuno-Oncology
Discovery & Development: Intra-tumoral Immuno & Combination Therapies & Small Molecules as IO Therapies
Translational & Preclinical and Clinical Development

Meet key decision makers representing large pharma & biotech companies:
Thomas Schurp - Vice President, PRTH-101 and Protein Sciences, Partheon Therapeutics
Shilpa Keerthivasan, Prinicipal Scientist, Bristol Myers Squibb
Floyd Romesberg, Director, Sanofi
Keegan Cooke, Senior Scientist, Amgen


View the agenda here - https://www.oxfordglobal.co.uk/immuno-se ries-us/agenda/?utm_source=wcc&utm_mediu m=eventlisting&utm_campaign=immuno&utm_c ontent=immunous2023

Co-located with Biomarkers US 2023 attendees receive access to both events. For more information contact [email protected]